Guardant Health, INC 10-Q quarterly reports

Guardant Health reported a 44% increase in Q2 2026 revenue to $335 million, driven by strong performance in oncology and screening tests, though net loss also widened.

Guardant Health reports strong revenue growth of 48% year-over-year for Q1 2026, driven by significant expansion in screening and oncology test volumes.

Guardant Health reported a 39% surge in third-quarter revenue, driven by strong adoption of its Shield colorectal cancer screening test and oncology portfolio, while significantly narrowing its net loss.

Guardant Health, a precision oncology company, reported significant revenue increases for Q2 and H1 2025, driven by the commercial launch of its Shield colorectal cancer screening test and growth in oncology test volumes, while also reducing its net loss despite increased operating expenses and navigating complex legal proceedings.

Guardant Health's Q1 2025 revenue increased by 21% compared to Q1 2024, driven by growth in oncology and biopharma segments, alongside the launch of the Shield screening test.

Guardant Health's Q3 2024 results show a significant increase in revenue, primarily driven by a 35% growth in precision oncology testing.

Guardant Health's Q2 2024 results show a significant increase in revenue, primarily driven by precision oncology testing, alongside ongoing investments in research and development.

Guardant Health's first quarter revenue increased by 31% year-over-year, driven by growth in both precision oncology testing and biopharmaceutical partnerships.